Bevacizumab: A Potential Addition to Treatment for Mesothelioma Victims
Malignant pleural mesothelioma (MPM) is an aggressive cancer, primarily brought on by asbestos exposure. Recent studies by Pavel A Levin and Jonathan E Dowell at the Division of Hematology/Oncology, University of Texas Southwestern Medical Center, have revealed adding bevacizumab to the combination of cisplatin and pemetrexed gives hope to selected mesothelioma victims by potentially extending …